Biogen Idec Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
317.01
+1.95 (0.62%)
Real-time:   9:40AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 314.44 - 317.87
52 week 230.25 - 358.89
Open 315.09
Vol / Avg. 855.00/1.57M
Mkt cap 74.86B
P/E 30.00
Div/yield     -
EPS 10.57
Shares 236.16M
Beta 1.23
Inst. own 92%
Jan 27, 2015
Q4 2014 Biogen Idec Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Oct 22, 2014
Q3 2014 Biogen Idec Inc Earnings Release
Oct 22, 2014
Q3 2014 Biogen Idec Inc Earnings Call - Webcast
Sep 23, 2014
Iraqi Islamic Bank for Investment and Development Annual Shareholders Meeting (Estimated)
Sep 8, 2014
Biogen Idec Inc at Morgan Stanley Healthcare Conference
Sep 4, 2014
Biogen Idec Inc at Citi Biotech Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 34.30% 27.11%
Operating margin 45.89% 36.25%
EBITD margin - 43.59%
Return on average assets 25.96% 17.09%
Return on average equity 34.39% 23.90%
Employees 6,850 -
CDP Score - 92 B

Address

225 BINNEY STREET
CAMBRIDGE, MA 2142
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company�s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 55
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Pharmaceutical Operations and Technology
Age: 51
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 59
Bio & Compensation  - Reuters
Tony Kingsley Executive Vice President - Global Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Executive Vice President - Research and Development
Age: 56
Bio & Compensation  - Reuters
Spyros Artavanis-Tsakonas Ph.D. Senior Vice President, Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters